We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boeing Reports Second-Quarter Commercial & Defense Deliveries
Read MoreHide Full Article
The Boeing Company (BA - Free Report) recently announced program deliveries across its commercial and defense operations for the second quarter of 2020. The figures show a massive 77.8% decline in commercial shipments from the previous year. However, the company’s defense shipments increased 18.9% year over year.
Combining both segments, Boeing’s total deliveries in the second quarter of 2020 were a mere 64 units compared with 127 units delivered in the year-ago quarter.
Q2 Commercial Deliveries
Boeing reported commercial deliveries of only 20 airplanes in second-quarter 2020, declining significantly year over year, primarily led by dismal 737 jet deliveries and comparatively lower deliveries of the 787 Dreamliner.
Delivery of the single-aisle 737 jets fell to four in the quarter from 24 a year ago. Shipments of the 777 model totaled four compared with 12 in the previous year’s second quarter. Shipments of the 787 Dreamliner totaled seven compared with 42 delivered in the year-ago period. The company delivered only four 767 jets during the quarter compared with 10 767 jets sold in the year-ago quarter.
Factors Leading to Poor Delivery Figures
Over the past few quarters, demand for Boeing's 737 jets has relatively remained low, following the consecutive crashes of its two 737 Max 8 jets in March 2019. Furthermore, as the impacts from the coronavirus pandemic continue to cripple aircraft demand, Boeing had to again encounter a significant drop in aircraft deliveries.
Due to the COVID-19 crisis, the company's operations were severely halted, including a shutdown of its commercial airplane production for a few weeks, as stated by Greg Smith, Boeing’s executive vice president of Enterprise Operations, chief financial officer and interim leader of Communications. Moreover, as air traffic slowed sharply due to the prolonged pandemic impacts, new aircraft that were supposed to get delivered are now lying idle in Boeing's manufacturing plants.
Boeing vs Airbus
Against the 20 aircraft deliveries made by Boeing, Airbus SE (EADSY - Free Report) remained ahead in terms of deliveries made, as the European aircraft giant delivered a total of 74 commercial aircraft in the second quarter of 2020. Evidently, in terms of commercial deliveries, Boeing’s arch-rival remained a step ahead during the second quarter.
A Brief Look at Boeing’s Defense Deliveries
Over the past few years, the United States along with many other nations has strategically strengthened and increased its defense spending due to the rising worldwide geopolitical tensions. Notably, such increased spending has been boosting defense deliveries made by defense giants, such as Boeing, Lockheed Martin (LMT - Free Report) and others.
In its defense and space business, Boeing’s deliveries totaled 44 in second-quarter 2020, which improved from 37 dispatched in the year-ago period.
Price Movement
Boeing’s stock has improved 22% in the past three months against the industry’s decline of 2.6%.
Hexcel Corp. delivered a four-quarter earnings beat of 1.16%, on average. The company has a long-term earnings growth rate of 5.6%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Boeing Reports Second-Quarter Commercial & Defense Deliveries
The Boeing Company (BA - Free Report) recently announced program deliveries across its commercial and defense operations for the second quarter of 2020. The figures show a massive 77.8% decline in commercial shipments from the previous year. However, the company’s defense shipments increased 18.9% year over year.
Combining both segments, Boeing’s total deliveries in the second quarter of 2020 were a mere 64 units compared with 127 units delivered in the year-ago quarter.
Q2 Commercial Deliveries
Boeing reported commercial deliveries of only 20 airplanes in second-quarter 2020, declining significantly year over year, primarily led by dismal 737 jet deliveries and comparatively lower deliveries of the 787 Dreamliner.
Delivery of the single-aisle 737 jets fell to four in the quarter from 24 a year ago. Shipments of the 777 model totaled four compared with 12 in the previous year’s second quarter. Shipments of the 787 Dreamliner totaled seven compared with 42 delivered in the year-ago period. The company delivered only four 767 jets during the quarter compared with 10 767 jets sold in the year-ago quarter.
Factors Leading to Poor Delivery Figures
Over the past few quarters, demand for Boeing's 737 jets has relatively remained low, following the consecutive crashes of its two 737 Max 8 jets in March 2019. Furthermore, as the impacts from the coronavirus pandemic continue to cripple aircraft demand, Boeing had to again encounter a significant drop in aircraft deliveries.
Due to the COVID-19 crisis, the company's operations were severely halted, including a shutdown of its commercial airplane production for a few weeks, as stated by Greg Smith, Boeing’s executive vice president of Enterprise Operations, chief financial officer and interim leader of Communications. Moreover, as air traffic slowed sharply due to the prolonged pandemic impacts, new aircraft that were supposed to get delivered are now lying idle in Boeing's manufacturing plants.
Boeing vs Airbus
Against the 20 aircraft deliveries made by Boeing, Airbus SE (EADSY - Free Report) remained ahead in terms of deliveries made, as the European aircraft giant delivered a total of 74 commercial aircraft in the second quarter of 2020. Evidently, in terms of commercial deliveries, Boeing’s arch-rival remained a step ahead during the second quarter.
A Brief Look at Boeing’s Defense Deliveries
Over the past few years, the United States along with many other nations has strategically strengthened and increased its defense spending due to the rising worldwide geopolitical tensions. Notably, such increased spending has been boosting defense deliveries made by defense giants, such as Boeing, Lockheed Martin (LMT - Free Report) and others.
In its defense and space business, Boeing’s deliveries totaled 44 in second-quarter 2020, which improved from 37 dispatched in the year-ago period.
Price Movement
Boeing’s stock has improved 22% in the past three months against the industry’s decline of 2.6%.
Zacks Rank & A Key Pick
Boeing currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the same sector is Hexcel Corp. (HXL - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hexcel Corp. delivered a four-quarter earnings beat of 1.16%, on average. The company has a long-term earnings growth rate of 5.6%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>